PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an...
Christopher Boerner Bristol Myer Squibb Samit Hirawat Bristol Myers Squibb Gordon Dyal Co Karuna Therapeutics Inc
Source: marketscreener.com